Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Firms Tighten Tysabri Indication To Gain Panel Endorsement For Crohn’s

Executive Summary

Given safety issues linked to Biogen Idec/Elan's Tysabri (natalizumab), the companies are narrowing the scope of the requested Crohn's disease indication from that initially proposed and studied in the clinical trials

You may also be interested in...



Tysabri For Crohn’s: Risk Management Is Same, But Could Be Higher Hurdle

The approval of Biogen Idec/Elan's multiple sclerosis treatment Tysabri (natalizumab) for Crohn's disease will expand the use of the product's multi-layered risk management program

Tysabri For Crohn’s: Risk Management Is Same, But Could Be Higher Hurdle

The approval of Biogen Idec/Elan's multiple sclerosis treatment Tysabri (natalizumab) for Crohn's disease will expand the use of the product's multi-layered risk management program

Strict Tysabri Risk Management Plan Drives Panel Support For Crohn’s

A highly restrictive risk management program for Biogen Idec/Elan's Tysabri swayed a joint advisory panel to recommend the product's approval for a Crohn's disease indication July 31 despite modest efficacy data and remaining safety concerns

Related Content

UsernamePublicRestriction

Register

PS048645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel